You can view the research column published every month by SMC Laboratories.
2025.01.29
Positive control for UUO kidney fibrosis
We would like to introduce about a newly established positive control – an ALK5 inhibitor – for ou…
READ MORE
2025.01.29
Adenine-induced nephropathy model
We would like to introduce our Adenine-induced nephropathy mouse model, a chronic kidney disease (CKD) model. …
READ MORE
2025.01.29
Biomarker for kidney damage in Adriamycin model
We would like to introduce a non-invasive biomarkers for kidney disease models. Urine NGAL level…
READ MORE
2025.01.29
Adriamycin-induced nephropathy model
We would like to introduce a chronic kidney disease (CKD) and our Adriamycin-induced nephropathy (ADR) mouse m…
READ MORE
2025.01.28
Supporting non-clinical immunotherapy drug development for HCC; new utilization of STAM HCC model
We would like to introduce the features of the STAMTM-HCC/IO+ model as a liver cancer model. For your referenc…
READ MORE
2025.01.28
[New Data!] Etrasimod in IBD Mouse Models
We are excited to share new efficacy data for Etrasimod (VELSIPITY) in inflammatory bowel disease (IBD) mouse …
READ MORE
2024.04.08
【Hot data】 Resmetirom (MGL-3196) evaluation data available in STAMTM model
MASH
Resmetirom
STAM
As you may already know, the United States Food and Drug Administration (FDA) announced the approval of Rezdif…
READ MORE
2024.03.21
What is the best non-clinical liver cancer model with 100% cancer incidence rate and suitable for liver cancer assessment?
If you are considering a drug evaluation study for liver cancer using a mouse model, our STAMTM-HCC/IO+ model …
READ MORE
2024.03.19
[ Breaking News! ] First MASH treatment approved by FDA
On March 14th, industry-altering news was published. Do you know already what we are talking about? The United…
READ MORE
2024.03.15
[Existing compounds] that have advanced to clinical trials will accelerate the launch of your drugs.
If you are planning to launch your therapeutic drug, you should select disease mouse models that have shown ac…
READ MORE
